Primecap Management Co. CA Purchases 372,180 Shares of Glaukos Co. (NYSE:GKOS)

Primecap Management Co. CA boosted its position in Glaukos Co. (NYSE:GKOS) by 43.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,220,815 shares of the medical instruments supplier’s stock after buying an additional 372,180 shares during the quarter. Primecap Management Co. CA owned approximately 2.42% of Glaukos worth $144,483,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of GKOS. Quadrant Capital Group LLC grew its holdings in shares of Glaukos by 54.8% in the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. increased its position in shares of Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 1,465 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after purchasing an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos in the 2nd quarter valued at approximately $187,000. Finally, LVW Advisors LLC bought a new position in shares of Glaukos in the second quarter valued at $213,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity at Glaukos

In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares in the company, valued at approximately $3,614,280. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the sale, the director now directly owns 30,119 shares in the company, valued at $3,614,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,500 shares of company stock worth $5,099,000. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Down 2.2 %

GKOS stock opened at $121.58 on Wednesday. The business’s fifty day moving average price is $124.57 and its two-hundred day moving average price is $110.63. The stock has a market capitalization of $6.12 billion, a price-to-earnings ratio of -42.22 and a beta of 1.03. Glaukos Co. has a fifty-two week low of $59.22 and a fifty-two week high of $136.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $88.86 million. During the same quarter in the previous year, the company earned ($0.55) EPS. The business’s revenue was up 19.0% on a year-over-year basis. On average, equities analysts anticipate that Glaukos Co. will post -2.18 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on GKOS shares. Citigroup cut shares of Glaukos from a “buy” rating to a “neutral” rating and increased their price target for the company from $130.00 to $132.00 in a research note on Wednesday, July 10th. BTIG Research lifted their price target on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Stifel Nicolaus upped their price objective on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC lifted their target price on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Truist Financial restated a “buy” rating and issued a $145.00 price target (up previously from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $129.82.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.